CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,427,935 | +218.6% | 699,392 | +134.0% | 0.00% | +300.0% |
| Q2 2023 | $3,272,681 | +254.2% | 298,875 | +3.8% | 0.00% | – |
| Q1 2022 | $924,000 | +3.0% | 287,914 | +1.9% | 0.00% | – |
| Q4 2021 | $897,000 | -23.2% | 282,669 | -7.6% | 0.00% | – |
| Q3 2021 | $1,168,000 | -13.8% | 305,847 | -1.6% | 0.00% | – |
| Q2 2021 | $1,355,000 | -17.2% | 310,887 | -13.8% | 0.00% | -100.0% |
| Q1 2021 | $1,637,000 | -12.7% | 360,578 | +10.4% | 0.00% | 0.0% |
| Q4 2020 | $1,875,000 | +2.9% | 326,711 | +29.8% | 0.00% | 0.0% |
| Q3 2020 | $1,822,000 | +99.6% | 251,720 | -3.8% | 0.00% | – |
| Q2 2020 | $913,000 | +56.6% | 261,718 | -33.5% | 0.00% | – |
| Q1 2020 | $583,000 | -62.0% | 393,585 | -49.7% | 0.00% | -100.0% |
| Q4 2019 | $1,535,000 | -9.9% | 783,188 | +135.4% | 0.00% | 0.0% |
| Q3 2019 | $1,704,000 | -30.8% | 332,753 | -3.3% | 0.00% | 0.0% |
| Q2 2019 | $2,463,000 | – | 344,046 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,641,804 | $7,454,000 | 6.54% |
| COMMODORE CAPITAL LP | 2,983,513 | $13,545,000 | 5.40% |
| Foresite Capital Management IV, LLC | 1,787,094 | $8,113,000 | 0.97% |
| Avoro Capital Advisors LLC | 10,300,000 | $46,762,000 | 0.81% |
| Boxer Capital, LLC | 4,000,000 | $18,160,000 | 0.62% |
| Sio Capital Management, LLC | 562,339 | $2,553,000 | 0.52% |
| ACUTA CAPITAL PARTNERS, LLC | 315,341 | $1,432,000 | 0.52% |
| CM Management, LLC | 150,000 | $681,000 | 0.51% |
| APIS CAPITAL ADVISORS, LLC | 120,000 | $545,000 | 0.50% |
| Versant Venture Management, LLC | 543,753 | $2,469,000 | 0.48% |